Form 8-K - Current report:
SEC Accession No. 0001104659-25-039710
Filing Date
2025-04-28
Accepted
2025-04-28 06:31:44
Documents
14
Period of Report
2025-04-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2512890d1_8k.htm   iXBRL 8-K 35825
2 EXHIBIT 10.1 tm2512890d1_ex10-1.htm EX-10.1 811526
  Complete submission text file 0001104659-25-039710.txt   1190799

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA uthr-20250425.xsd EX-101.SCH 3011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE uthr-20250425_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE uthr-20250425_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2512890d1_8k_htm.xml XML 3574
Mailing Address 1000 SPRING ST SILVER SPRING MD 20910
Business Address 1000 SPRING ST SILVER SPRING MD 20910 3016089292
UNITED THERAPEUTICS Corp (Filer) CIK: 0001082554 (see all company filings)

EIN.: 521984749 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26301 | Film No.: 25875872
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)